Lupus nephritis (LN) is a severe and frequent complication of systemic lupus erythematosus (SLE). Untreated cases very often lead to patients' death; therefore, it is important to use markers sensitive and specific enough for the diagnosis and subsequent monitoring of nephritis. Autoantibodies against double-stranded DNA (anti-dsDNA) are believed to play a major role in SLE in general and so their significance in prediction and monitoring of glomerular inflammation is low. For prediction of renal flares and effective, well-timed therapy, it is required to have an appropriate marker available. In our study, we have tested sera of 85 SLE patients with or without LN. The criterion for LN determination was the degree of proteinuria (persistent proteinuria > 0.5 g/day, according to ACR criteria for LN). Disease activity was described by SLE disease index (SLEDAI) score, renal functions were stated according to British Isles Lupus Assessment Group score. There were anti-C1q, total anti-dsDNA and high-avidity anti-dsDNA detected in the patients' sera. We did not find any significant difference in average SLEDAI value between patients with renal and non-renal organ complications. Positivity of anti-C1q was more frequent in patients with nephritis than in those without any history of renal disease (58.3 vs. 39.1%). Higher prevalence of these antibodies was evident in patients with clinically active LN than in those without renal improvement (73.1 vs. 39.1%). When comparing anti-C1q with antibodies against structures of DNA, significant differences were found in case of high avidity anti-dsDNA. Our results have confirmed the studies showing that anti-C1q antibodies could serve as a reliable serological marker of LN activity along with other laboratory tests. Detection of anti-C1q together with high avidity anti-dsDNA antibodies seems to be a good algorithm for the prediction of possible renal flares in SLE patients.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune, clinically heterogeneous disease. Prevalence varies with ethnicity, but is estimated to be about 1 per 1000 overall, with a female to male ratio of 10:1. Kelly et al. (2002) stated that SLE primarily affects women of child-bearing age (F:M ratio, 9:1) and has a prevalence of approximately 1 per 2500. Among African American populations, SLE is 3 times more prevalent than in European Americans, manifests at a younger age and is more severe than in other American populations. SLE can affect every organ in the body. Glomerulonephritis is a severe complication of SLE. It is the most frequent clinical feature of SLE and untreated cases very often lead to patients' death. The prevalence of lupus nephritis (LN) oscillated from 29 to 65% in lupus patients (Venuturupallli &Wallace, 2007) . The spectrum of renal involvement differs from asymptomatic proteinuria or hematuria to overt nephritic and nephrotic syndromes. Proteinuria is the most common manifestation. Several autoantibodies, especially those against double stranded DNA (anti-dsDNA) are believed to play a major role in the induction of glomerular inflammation (Berden, 2003 , Mortensen & Rekvig, 2010 , Rekvig & Nossent, 2003 . However, more sensitive and specific markers for the clinical detection of relapse or renal disease in patients with SLE are needed for early treatment to prevent severe clinical complications (i.e. renal insufficiency).The heterogeneity of SLE and its flares in study design as well as the outcome measures may contribute to the utility of future LN clinical experiments. In addition to the accuracy of outcome assessment tools in SLE, inclusion of novel biomarkers in these trials may increase the feasibility of identification of patients who would benefit from the newer regimens (Mok, 2010 ). In population of SLE patients, the antibodies against collagen-like portion of C1q complement component (anti-C1q) have been shown to be specific for the LN (Cornec et al., 2009 ). Anti-C1q, similarly as anti-dsDNA, belongs to the natural autoantibodies repertoire. In healthy population, they are present at low concentrations and are characterised by low avidity (Siegert et al., 1993b) . Genetic predisposition and outdoor influences switch these natural autoantibodies into pathological high avidity anti-C1q IgG. The presented study is a part of retrospective analysis of serum samples obtained from SLE patients suffering with different organ complications of different intensity. In this particular research, we try to determine the prevalence of anti-C1q antibodies in SLE patients with or without LN and compare the correlation of anti-C1q antibodies levels with reactivity and avidity of autoantibodies against the structure of DNA (anti-dsDNA and high avidity anti-dsDNA).
MATERIAL AND METHODS
A total of 85 patients (75 women and 10 men) with SLE (from the National Institute of Rheumatic Diseases, Piešťany, Slovakia) were collected during the period from July 2007 to January 2008. All patients fulfilled the ACR diagnostics criteria for SLE (Hochberg, 1997 (Weening, 2004 ) was used to define the histological renal lesions. Renal disease activity in patients with SLE was evaluated by the British Isles Lupus Assessment Group (BILAG) renal score (Gordon, 2003) . Clinical symptoms of nephritis were suspected if urinalysis showed proteinuria > 0.5 g/24 h urine collection and/or haematuria or cellular casts with or without increased serum creatinine (Boumpas & Balow, 1998) . The patients' serum samples were classified according to proteinuria levels into three groups: Group (1) with proteinuria higher than 2.0 g/24 h (category BILAG A), Group (2) with proteinuria 0.5-2.0 g/24 h (category BILAG B) and Group (3) with normal total protein in urine but with proteinuria in the history (category BILAG C, D). The control group consisted of SLE patients without LN (category BILAG E). The control samples were divided into two groups 
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according to the SLE disease index (SLEDAI) score at the time of sampling -SLEDAI > 4 and SLEDAI 0-4. The SLE activity at periodic serum sampling was defined based on SLEDAI index. The renal functions expressed by proteinuria values in particular patients groups are shown in Table 2 . All patients entered the study after giving their informed written consent.
AUTOANTIBODY DETERMINATION
Enzyme-linked immunosorbent assay (ELISA) commercial kits were used to determine anti-dsDNA (Bindazyme Anti dsDNA EIA Kit, Binding Site, UK), high avidity anti-dsDNA (Farrzyme Anti dsDNA Kit, Binding Site, UK), antinucleosomal (Anti-Nucleosomes ELISA IgG, Euroimmun, D) and anti-C1q (Bindazyme Anti C1q EIA Kit, Binding Site, UK) autoantibodies in each serum sample. To ensure that only antibodies recognising the conformational modified epitopes of C1q but not immune complexes or anti-dsDNA with high avidity in case of Farrzyme kit were detected, systems with high-salt buffer were used. Avidity of antibodies was determined by modification of commercial ELISA kits via elution-denaturating method (Hedman & Sepälä, 1988) . At preliminary testing, 3M, 4M and 6M urea was analysed for avidity determination, the urea concentration of 4M was chosen as optimal.
STATISTICAL ANALYSES
All statistical analyses were performed using Excel software (Microsoft, USA). The statistical significance of differences between the groups was determined using a t-test.
RESULTS
Renal impairment was reflected in the evaluation of disease activity by SLEDAI score (Table 3) . Patients with manifested proteinuria had the highest averages of SLEDAI score. SLEDAI values ranged from 4 to 37 in all patients. There was no significant difference in SLEDAI score between the patients with proteinuria higher than 2.0 g/24 h (BILAG A) or the group of patients with proteinuria 0. The mean level of anti-C1q in the group with proteinuria>2.0 g/24 h was significantly higher compared to the group with proteinuria 0.5-2.0 g/24 h or inactive LN (220.3, 65.0 and 4.8 U/ml, p < 0.05). Anti-C1q in the patients with inactive LN was lower than in both control groups, mean levels of anti C1q were 10.5 U/ml in the control group with SLEDAI > 4 and 11.7 U/ml in the control group with SLEDAI 0-4. The difference is not significantly important. Anti-C1q average levels in patients with inactive LN and control groups did not exceed the upper limit of anti-C1q normal range (Figure 1 ). In 13 of 49 patients without LN and with no previous renal complications, anti-C1q antibodies were detected at the time of serum collection. Three of these 13 patients developed LN within 3 years. In these patients, we found anti-C1q antibody levels higher than 25 U/ml. In two patients, we observed increased levels of anti-C1q at consecutive examinations within 6 months combined with renal flares associated with increased proteinuria. For example, in one patient, the anti-C1q increased from 17.5 to 75.6 U/ml, the dynamics of proteinuria levels was similar (0.12 g/24 h to 1.4 g/24 h). When comparing anti-C1q with antibodies against the structures of DNA, we did not find a significant correlation between the antibody reactivity. As anti-dsDNA antibodies are highly specific for SLE in general; their high levels were also found in control patients groups without renal involvement. Levels of anti-dsDNA reflect mild dependence on proteinuria grade in evaluated groups. The highest levels of anti-dsDNA were found in patients with active LN. Only slightly elevated levels of anti-dsDNA were observed in the group within 
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Clinical significance of anti-C1q antibodies in SLE active LN. Reactivity of anti-dsDNA in patients with inactive LN was thus comparable with control groups. Similarly, the highest levels of high avidity anti-dsDNA have been detected in patients group with elevated proteinuria. There were found significant differences between both patients group with proven proteinuria and patients with inactive LN. In relation to renal involvement, anti-nucleosome antibody levels tend to have similar tendency to anti-dsDNA in SLE patients (Stiborová et al., 2013 a,b) . The specificity of anti-C1q for renal involvement in patients with SLE was proven in this trial. There were also found differences, but not significant, between anti-C1q levels in patients with proteinuria and patients without renal complications. The lowest levels of autoantibodies were detected in the inactive LN group, but with LN in patient history, probably as a consequence of previous renal flares immunosuppression therapy.
DISCUSSION

LN is one of the most serious organ complications in SLE.
Renal involvement is associated with significant prevalence of morbidity and mortality in SLE patients (Garcia et al., 1996) . The clinical heterogeneity of this disease mirrors its complex etiopathogenesis, which highlights the importance of genetic factors and individual susceptibility. Xing et al. (2005) found that the prevalence of renal disease was higher in families with affected male relatives than in families with no affected male relatives. Xing et al. (2005) concluded that the multiplex SLE families with at least one affected male relative represent a substantial subset of multiplex SLE families. New specific and sensitive predictive markers for LN are being investigated intensively.The aim of our study was to confirm the role of anti-C1q antibodies in SLE patients with renal involvement and to highlight the relationship to other diagnostically significant antibody. Levels of antiC1q antibodies are a noninvasive biological marker of LN activity. Its sensitivity and specificity is higher for disease activity monitoring than traditional markers, such as C3/C4 consumption or anti-dsDNA (Li, 2013) . Laboratory findings in urine express the degree of renal impairment. In our study, the value of proteinuria was selected as a marker of renal involvement in SLE patients. Urine biomarkers appear to be more encouraging than serum biomarkers possibly because they are the direct products or consequences of kidney inflammation or injury (Mok, 2010) .
As cytokines are important participants in pathogenesis of LN, they are tested for their potential biomarker ability (Misra & Gupta, 2015) . The degree of renal damage correlates with urinary levels of monocyte chemoattractant protein-1 (MCP-1) (Alharazy et al. 2014) or urinary levels of neutrophil gelatinase lipocalin (NGAL) (Youssef et al. 2015 , Elewa et al. 2015 . Unfortunately, both these molecules are not specific for LN. Pathogenesis and activity of LN and severity of renal involvement are related to serum levels of interleukin-18 (IL-18) that reflects the degree of renal injury in lupus even in the absence of significant proteinuria regardless of the disease activity (El Bakry, 2015). Autoantibodies were proved to play a pivotal role in LN (Rekvig & Nossent, 2003) . Anti-dsDNA reactivity is not only of valuable benefit in the diagnosis of SLE, it has also crucial role in LN pathogenesis (Cornec, et al. 2009 ). Possible pathways of anti-dsDNA pathogenicity have been described previously by Rekvig & Nossent (2003) . Our results document that increased renal activity is associated with rising SLEDAI score as well as with reactivity of anti-DNA. At sites of glomerular injury, there are immune complexes present. The targets and mediators of autoantibody-related glomerular immune-complex deposition are nucleosomes that have been detected both in patients and murine models, even prior to the development of antibodies against anti-dsDNA and histone. Increasing levels of antibodies against structures of DNA (anti-DNA) are reported to be associated with the activity of LN as well as with general disease activity. In our study, similarly as in other publications, there are no differences in prevalence of anti-DNA in patients with and without nephritis (Marto et al., 2005) . Thus, increases in anti-DNA antibodies cannot clearly distinguish between renal and extrarenal relapses (Sinico et al., 2005) . 
CONCLUSION
The etiopathogenic importance of anti-C1q antibodies is indisputable. However, their relevance to the diagnosis of LN and associated LN flares has not been fully elucidated yet. Presented results confirm the findings that anti-C1q antibodies could serve as a reliable serological marker in the evaluation of LN activity along with other laboratory tests. Detection of anti-C1q together with high avidity anti-dsDNA antibodies seems to be good algorithm for prediction of possible renal flares in SLE patients.
